Rare People. Rare Medicines.
Who We Are
Cerium Pharmaceuticals is dedicated to creating efficacious therapies for patients with kidney diseases. Cerium is currently focused on developing the first drug approved for a very rare kidney disease called Primary Membranous Nephropathy (PMN). There are approximately 75,000 PMN patients in the US and approximately 3,000 newly diagnosed PMN patients per year.
What is PMN?
Primary membranous nephropathy (PMN) is a kidney disease that can cause excess protein in the urine, decreased kidney function and substantial reduction in the quality of life. Between 30 and 40% of patients with PMN eventually require dialysis or kidney transplant.
What is ACTH?
Adrenocorticotropic hormone (ACTH) is a polypeptide tropic hormone produced by and secreted by the anterior pituitary gland. ACTH is released in response to the release corticotropin-releasing hormone (CRH) by the hypothalamus. The primary function of ACTH is to stimulate the production and release of cortisol which helps your body manage stress.
Cerium intends to initiate a Phase 3 clinical trial in Primary Membranous Nephropathy (PMN) in Q2 2022
News & Events
Cerium Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) for Corticotropin (ACTH) porcine (synthetic), otherwise referred to as SNP-ACTH (1-39) Gel. This investigational agent is in development for the treatment of primary membranous nephropathy (PMN) a rare kidney disease that affects approximately 75,000 patients in the US.
Cerium Pharmaceuticals, Inc., a clinical stage biopharmaceuticals company focused on developing medicines for rare and orphan diseases, today announced that it has closed a $12 million Series B financing.